ContextPatients with nonvalvular atrial fibrillation (AF) have an increased risk of stroke and
other vascular events. ObjectiveTo compare the risk of vascular and bleeding events in …

This chapter about antithrombotic therapy in atrial fibrillation (AF) is part of the American
College of Chest Physicians Evidence-Based Guidelines Clinical Practice Guidelines (8th …

The choice of oral anticoagulant (OAC) for patients with atrial fibrillation (AF) may be
influenced by individual clinical features or by patterns of risk factors and comorbidities. We …

In patients with atrial fibrillation (AF) and an intermediate risk of stroke (CHADS 2 score= 1),
available evidence from clinical trials is inconclusive and the present guidelines for the …

Background The risk of stroke varies considerably across different groups of patients with
atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is associated with an increased …

Background Warfarin, despite its known limitations, is the reference standard treatment for
patients with AF and risk factors for stroke. We performed a meta-analysis of phase III trials …

Background: Oral anticoagulation reduces the risk of mortality in atrial fibrillation (AF), but
examination of the causes of death is essential to design new strategies to further reduce the …

BACKGROUND: Atrial fibrillation is associated with substantial mortality and morbidity from
stroke and thromboembolism. Despite an efficacious oral anticoagulation therapy (warfarin) …

Patients with atrial fibrillation (AF) have a high risk of stroke and mortality, which can be
considerably reduced by oral anticoagulants (OAC). Recently, four non-vitamin-K oral …

Background: Direct oral anticoagulants (DOACs) are increasingly used in place of warfarin,
but evidence about their effectiveness and safety in patients with valvular atrial fibrillation …